Search

Your search keyword '"Mattsson‐Carlgren, Niklas"' showing total 701 results

Search Constraints

Start Over You searched for: Author "Mattsson‐Carlgren, Niklas" Remove constraint Author: "Mattsson‐Carlgren, Niklas"
701 results on '"Mattsson‐Carlgren, Niklas"'

Search Results

1. Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability

3. Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests

14. Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology

15. Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease

18. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets

19. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease

22. Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration

23. Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization

25. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

26. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease

27. A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis

28. Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts

29. The impact of demographic, clinical, genetic, and imaging variables on tau PET status

30. Relevance of biomarkers across different neurodegenerative diseases

31. Correction to: Relevance of biomarkers across different neurodegenerative diseases

32. Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype

33. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

35. Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring

37. Author Correction: Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets

38. Associations between misfolded alpha‐synuclein aggregates and Alzheimer's disease pathology in vivo.

39. Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.

43. Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment

44. Identification of distinct and shared biomarker panels in different manifestations of cerebral small vessel disease through proteomic profiling

45. Medial temporal lobe atrophy patterns in early- versus late-onset amnestic Alzheimer's disease

46. Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest

49. Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment.

Catalog

Books, media, physical & digital resources